Biomaterials-based Approaches for Cardiac Regeneration

Vasu, Samhita; Zhou, Justin; Chen, Jeffrey; Johnston, Peter V.; Kim, Deok Ho

doi:10.4070/kcj.2021.0291

Cited by 20 publications

(12 citation statements)

References 99 publications

(172 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, administration of stem cells or progenitor cells into either failing heart or injured vasculature exhibits a poor cell survival, because the preexisting oxidative microenvironment causes the cell death by 90% and impairs their function (Sthijns et al., 2018 ; Tenreiro et al., 2021 ). Although a few numbers of innovative strategies, namely by using the complex biomaterial‐based cell delivery system, appear to circumvent this limitation and enhance stem cell viability, the current interventions are still insufficient (Mu et al., 2022 ; Vasu et al., 2021 ).…”

Section: Cardiovascular Regeneration: Current Strategies and Pitfallsmentioning

confidence: 99%

Targeting the redox system for cardiovascular regeneration in aging

Allemann,

Lee,

Beer

et al. 2023

Aging Cell

View full text Add to dashboard Cite

Cardiovascular aging presents a formidable challenge, as the aging process can lead to reduced cardiac function and heightened susceptibility to cardiovascular diseases. Consequently, there is an escalating, unmet medical need for innovative and effective cardiovascular regeneration strategies aimed at restoring and rejuvenating aging cardiovascular tissues. Altered redox homeostasis and the accumulation of oxidative damage play a pivotal role in detrimental changes to stem cell function and cellular senescence, hampering regenerative capacity in aged cardiovascular system. A mounting body of evidence underscores the significance of targeting redox machinery to restore stem cell self‐renewal and enhance their differentiation potential into youthful cardiovascular lineages. Hence, the redox machinery holds promise as a target for optimizing cardiovascular regenerative therapies. In this context, we delve into the current understanding of redox homeostasis in regulating stem cell function and reprogramming processes that impact the regenerative potential of the cardiovascular system. Furthermore, we offer insights into the recent translational and clinical implications of redox‐targeting compounds aimed at enhancing current regenerative therapies for aging cardiovascular tissues.

show abstract

Section: Cardiovascular Regeneration: Current Strategies and Pitfallsmentioning

confidence: 99%

Targeting the redox system for cardiovascular regeneration in aging

Allemann,

Lee,

Beer

et al. 2023

Aging Cell

View full text Add to dashboard Cite

show abstract

“…Mechanobiology is known to play a role in cardiac embryology, diseases, and regeneration, 91) but its function in cardiac reprogramming remains unclear. The key factor that determines the success or failure of reprogramming is the extracellular environment.…”

Section: Direct Cardiac Reprogrammingmentioning

confidence: 99%

Cardiovascular Regeneration via Stem Cells and Direct Reprogramming: A Review

et al. 2022

View full text Add to dashboard Cite

Author's summary Despite recent advancements in treatment strategies, cardiovascular disease such as heart failure remains a significant source of global mortality. Stem cell technology and cellular reprogramming are rapidly growing fields that will continue to prove useful in cardiac regenerative therapeutics. This review provides information on the role of human pluripotent stem cells (hPSCs) in cardiac regeneration and discusses the practical applications of hPSC-derived cardiomyocytes (CMCs). Moreover, we discuss the practical applications of hPSC-derived CMCs while outlining the relevance of directly-reprogrammed CMCs in regenerative medicine. This review critically summarizes the most recent advances in the field will help to guide future research in this developing area.

show abstract

“…Stem cell therapies, including embryonic (ESC), mesenchymal (MSC), induced pluripotent (iPSC), and others, have been widely explored both as functional tissue replacements and for their immunomodulatory effects [ 46 – 48 ]. However, the delivery of these cells alone is hindered by low cell retention and survival rates, contributing to poor therapeutic efficacy [ 49 ] and motivating the use of biomaterial delivery vehicles. Pharmacological approaches include the systemic or local delivery of exogenous cytokines, chemokines, and small molecule drugs.…”

Section: Introductionmentioning

confidence: 99%

Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches

Soni

D'Elia

Rodell

2023

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Ischemic heart failure (IHF) is a leading cause of morbidity and mortality worldwide, for which heart transplantation remains the only definitive treatment. IHF manifests from myocardial infarction (MI) that initiates tissue remodeling processes, mediated by mechanical changes in the tissue (loss of contractility, softening of the myocardium) that are interdependent with cellular mechanisms (cardiomyocyte death, inflammatory response). The early remodeling phase is characterized by robust inflammation that is necessary for tissue debridement and the initiation of repair processes. While later transition toward an immunoregenerative function is desirable, functional reorientation from an inflammatory to reparatory environment is often lacking, trapping the heart in a chronically inflamed state that perpetuates cardiomyocyte death, ventricular dilatation, excess fibrosis, and progressive IHF. Therapies can redirect the immune microenvironment, including biotherapeutic and biomaterial-based approaches. In this review, we outline these existing approaches, with a particular focus on the immunomodulatory effects of therapeutics (small molecule drugs, biomolecules, and cell or cell-derived products). Cardioprotective strategies, often focusing on immunosuppression, have shown promise in pre-clinical and clinical trials. However, immunoregenerative therapies are emerging that often benefit from exacerbating early inflammation. Biomaterials can be used to enhance these therapies as a result of their intrinsic immunomodulatory properties, parallel mechanisms of action (e.g., mechanical restraint), or by enabling cell or tissue-targeted delivery. We further discuss translatability and the continued progress of technologies and procedures that contribute to the bench-to-bedside development of these critically needed treatments. Graphical Abstract

show abstract

Biomaterials-based Approaches for Cardiac Regeneration

Cited by 20 publications

References 99 publications

Targeting the redox system for cardiovascular regeneration in aging

Targeting the redox system for cardiovascular regeneration in aging

Cardiovascular Regeneration via Stem Cells and Direct Reprogramming: A Review

Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches

Contact Info

Product

Resources

About